Callan Capital LLC Sells 1,813 Shares of Sanofi (NASDAQ:SNY)

Callan Capital LLC lowered its stake in shares of Sanofi (NASDAQ:SNY) by 12.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,900 shares of the company’s stock after selling 1,813 shares during the quarter. Callan Capital LLC’s holdings in Sanofi were worth $622,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of SNY. Allspring Global Investments Holdings LLC boosted its stake in shares of Sanofi by 434.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 50,583 shares of the company’s stock valued at $2,915,000 after purchasing an additional 41,117 shares in the last quarter. Foundations Investment Advisors LLC acquired a new stake in shares of Sanofi in the 3rd quarter valued at $248,000. Private Advisor Group LLC boosted its stake in shares of Sanofi by 2.6% in the 3rd quarter. Private Advisor Group LLC now owns 52,338 shares of the company’s stock valued at $3,016,000 after purchasing an additional 1,339 shares in the last quarter. International Assets Investment Management LLC acquired a new stake in shares of Sanofi in the 3rd quarter valued at $7,038,000. Finally, Brighton Jones LLC acquired a new stake in shares of Sanofi in the 3rd quarter valued at $205,000. Institutional investors own 14.04% of the company’s stock.

Sanofi Stock Up 0.6 %

Shares of NASDAQ SNY opened at $54.46 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The company has a market cap of $138.21 billion, a price-to-earnings ratio of 21.87, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. The firm’s 50-day simple moving average is $50.95 and its 200 day simple moving average is $52.53.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, research analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SNY has been the topic of several research reports. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $60.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.